BEIJING, July 25, 2014 /PRNewswire/ -- Sinovac Biotech
Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical
products in China, today announced
that it will release its unaudited financial results for the second
quarter ended June 30, 2014, after
market close on Thursday, August 14, 2014
EDT. The Company will host a conference call prior to the
market opening on Friday, August 15,
2014, at 8:00 a.m. EDT
(Friday, August 15, 2014 at
8:00 p.m. China Standard Time) to
review the Company's financial results and provide an update on
recent corporate developments.
To access the conference call, please dial 1-877-407-9039
(USA) or 1-201-689-8470
(International). A replay of the call will be available from
11 a.m. EDT on August 15, 2014, to August
29, 2014, at midnight. To access the replay, please dial
1-877-870-5176 (USA) or
1-858-384-5517 (International) and reference the replay pin number
13587706.
A live audio webcast of the call will also be available on the
Investor Relations section of the Company's website at
www.sinovac.com. A webcast replay will be available on the
Company's website for 30 days following the call, beginning
August 15, 2014.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacturing, and
commercialization of vaccines that protect against human infectious
diseases. Sinovac's product portfolio includes vaccines against
hepatitis A and B, seasonal influenza, H5N1 pandemic influenza
(avian flu), H1N1 influenza (swine flu), mumps and canine rabies.
In 2009, Sinovac was the first company worldwide to receive
approval for its H1N1 influenza vaccine, which it has supplied to
the Chinese Government's vaccination campaign and stockpiling
program. The Company is also the only supplier of the H5N1 pandemic
influenza vaccine to the government stockpiling program. Sinovac
has filed a new drug application with the China Food & Drug
Administration for its proprietary enterovirus 71 vaccine, having
been proven effective in preventing hand, foot and mouth disease in
infants and children during its Phase III trial. The company is
currently developing a number of new products including a
Sabin-strain inactivated polio vaccine, pneumococcal
polysaccharides vaccine. pneumococcal conjugate vaccine and
varicella vaccine. Sinovac primarily sells its vaccines in
China, while also exploring growth
opportunities in international markets. The Company has exported
select vaccines to Mongolia,
Nepal, the Philippines and Mexico, and was recently granted a license to
commercialize its hepatitis A vaccine in Chile. For more information, please visit the
Company's website at www.Sinovac.com .
Contact
Sinovac Biotech Ltd.
Helen Yang / Chris Lee
Tel: +86-10-8279-9659 / 9696
Fax: +86-10-6296-6910
Email: ir@sinovac.com
ICR Inc.
Bill Zima
U.S: 1-646-308-1707
Email: william.zima@icrinc.com
SOURCE Sinovac Biotech Ltd.